Aim

Outcomes with everolimus-eluting stents (EES) are excellent in multiple randomized controlled trials. There is a need regarding their use in a real-world scenario. We report our experience with EES at 2 years.

Methods

A total of 403 consecutive patients (mean age 64+12 years, 71% male) who underwent percutaneous coronary intervention (PCI) with EES (PROMUS, Boston Scientific, Natick, MA, USA, or XIENCE V, Abbott Vascular, Santa Clara, CA, USA) were included in this study. We looked at reviewing mortality, myocardial infarction (MI) and target vessel revascularization (TVR) over a 2-year period. All patients received aspirin and 75 mg/day clopidogrel for a minimum of 6 months.

Methods

A total of 403 consecutive patients (mean age 64+12 years, 71% male) who underwent percutaneous coronary intervention (PCI) with EES (PROMUS, Boston Scientific, Natick, MA, USA, or XIENCE V, Abbott Vascular, Santa Clara, CA, USA) were included in this study. We looked at reviewing mortality, myocardial infarction (MI) and target vessel revascularization (TVR) over a 2-year period. All patients received aspirin and 75 mg/day clopidogrel for a minimum of 6 months.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Coronary stenting with MGuard: extended follow-up of first human trial
2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
3. Statin improves outcome of patients presenting with first acute myocardial infarction
4. Risk factors and impact of contrast left ventriculogram on incidence of contrast-induced nephropathy: is left ventriculogram really necessary?

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree